| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | G Reid | |
| T Koyama | |||
| K Anukam | |||
| P2860 | cites work | Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland | Q21128674 |
| A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 | ||
| Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis | Q28212121 | ||
| Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial | Q28237525 | ||
| Response to the article: McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-22 | Q28285983 | ||
| Inappropriate use of meta-analysis to estimate efficacy of probiotics | Q28286886 | ||
| Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children | Q29028534 | ||
| Bacterial DNA within granulomas of patients with Crohn's disease--detection by laser capture microdissection and PCR. | Q33205888 | ||
| Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. | Q33231186 | ||
| Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials | Q33255725 | ||
| Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis | Q33258217 | ||
| Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. | Q33270858 | ||
| Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. | Q51792257 | ||
| Mycobacterium avium sub. paratuberculosis in tissue samples of Crohn's disease patients. | Q54729747 | ||
| Probiotics in gastroenterology | Q57006085 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| Bifidobacterium from fermented milks: survival during gastric transit | Q70179236 | ||
| Safety of lactobacillus strains as probiotic agents | Q74455019 | ||
| Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers | Q74545706 | ||
| Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study | Q77723352 | ||
| Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis | Q78619472 | ||
| Safe and efficacious probiotics: what are they? | Q79814750 | ||
| Post-infectious irritable bowel syndrome | Q79890359 | ||
| Probiotics in the prevention of traveler's diarrhea: meta-analysis | Q80141318 | ||
| Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype | Q81077325 | ||
| Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study | Q83006425 | ||
| Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
| A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
| Effect of Bifidobacterium bifidum fermented milk on Helicobacter pylori and serum pepsinogen levels in humans | Q40129589 | ||
| G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced suppression of TNF production in macrophages | Q40247336 | ||
| Diarrhoea associated with antibiotic use. | Q42592374 | ||
| Microbiologic characteristics of Lactobacillus products used for colonization of the vagina. | Q43916727 | ||
| Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome | Q44229588 | ||
| Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors | Q44333170 | ||
| Association between fecal hydrogen sulfide production and pouchitis | Q45300584 | ||
| Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens | Q46134666 | ||
| Germs, gas and the gut; the evolving role of the enteric flora in IBS. | Q46924811 | ||
| Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice | Q50073557 | ||
| Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). | Q50901084 | ||
| Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion | Q51607341 | ||
| The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study | Q33432290 | ||
| A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating | Q33434046 | ||
| Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients | Q33439096 | ||
| Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea | Q33451610 | ||
| Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. | Q33711137 | ||
| Differentiation of Lactobacillus Species by Molecular Typing. | Q33714612 | ||
| Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea | Q34017677 | ||
| Drosophila lifespan enhancement by exogenous bacteria | Q34342471 | ||
| Evolutionary perspective on dietary intake of fibre and colorectal cancer | Q34549366 | ||
| Lactic acid bacteria as probiotics. | Q34552168 | ||
| Saccharomyces cerevisiae fungemia: an emerging infectious disease | Q34557580 | ||
| Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. | Q34572969 | ||
| Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients | Q34580564 | ||
| Culture-independent analysis of probiotic products by denaturing gradient gel electrophoresis | Q34876636 | ||
| New scientific paradigms for probiotics and prebiotics | Q35180429 | ||
| T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans | Q35355393 | ||
| Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis | Q35596747 | ||
| The importance of guidelines in the development and application of probiotics. | Q36002824 | ||
| Probiotics and the treatment of infectious diarrhea | Q36063166 | ||
| Probiotics in the prevention and treatment of gastrointestinal infections | Q36552642 | ||
| VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases | Q36563414 | ||
| Bacteria in the pathogenesis of inflammatory bowel disease. | Q36581339 | ||
| Bacterial overgrowth as a cause of irritable bowel syndrome | Q36629354 | ||
| Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. | Q36735647 | ||
| Use of probiotics in pediatrics: rationale, mechanisms of action, and practical aspects | Q36824470 | ||
| Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii | Q36862309 | ||
| Bacteroides thetaiotaomicron in the gut: molecular aspects of their interaction | Q36865794 | ||
| Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression | Q37521881 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Canada | Q16 |
| gastroenterology | Q120569 | ||
| probiotics | Q1816730 | ||
| P304 | page(s) | 169-175 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Canadian Journal of Gastroenterology | Q15749648 |
| P1476 | title | Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend? | |
| P478 | volume | 22 |
| Q37020637 | Addition of clidinium-C to the 14-day proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication |
| Q43167799 | Probiotics in the arabian gulf region |
| Q54354634 | Safety and persistence of orally administered human Lactobacillus sp. strains in healthy adults. |
| Q37401581 | Unraveling mechanisms of action of probiotics. |
Search more.